{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:27:59Z","timestamp":1730870879429,"version":"3.28.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Was ist neu<\/jats:title><jats:p>Menopausale Beschwerden erhalten mehr Aufmerksamkeit Seit 2022 ist die Menopause ein \u201ehei\u00dfes\u201c Gespr\u00e4chsthema auf vielen Kan\u00e4len. Patientinnen fordern zunehmend Rat und Abhilfe bei Beschwerden. Dies hat zu einem Boom von Social-Media-Foren, Menopause-Zentren und Internet-Angeboten gef\u00fchrt.<\/jats:p><jats:p>\n            Neuer Begriff f\u00fcr vulvavaginale-Atrophie: genitourin\u00e4res Syndrom der Menopause (GSM) GSM umfasst urogenitale Symptome wie Scheidentrockenheit (vaginale Trockenheit), Brennen und Juckreiz, urologische Beschwerden wie Dysurie, Kontaktblutungen, und Schmerzen bei Geschlechtsverkehr. GSM entsteht, wenn ein Estrogenmangel \u00fcber mehr als 3 Monate besteht und dann zu einer Ver\u00e4nderung des vaginalen Mikrobioms und Atrophie des Vaginalepithels f\u00fchren kann. Diese Ver\u00e4nderungen k\u00f6nnen die Lebensqualit\u00e4t \u00fcber viele Jahre hinweg deutlich einschr\u00e4nken und sind gut und risikoarm lokal therapierbar.<\/jats:p><jats:p>\n            Wenn Frauen sich nicht mehr wiedererkennen \u2013 symptomatische Perimenopause Brustspannen, Schlafst\u00f6rungen, Stimmungsschwankungen, Palpitationen, Panikattacken, Gelenkschmerzen, Schwindelgef\u00fchle, Kopfschmerzen, und kognitive Aussetzer (\u201ebrain fog\u201c) wurden in einer internationalen Online-Studie mit 2400 Frauen (35\u201355 Jahre) von mehr als 20% der Teilnehmerinnen noch vor der Menopause benannt. Viele Frauen erleben pl\u00f6tzlich Symptome, die sie als \u00fcberw\u00e4ltigend empfinden und nicht einordnen k\u00f6nnen, und die \u00c4ngste vor einer schweren Erkrankung ausl\u00f6sen k\u00f6nnen. Nicht selten f\u00fchrt dies dazu, umfangreiche Abkl\u00e4rungen zu veranlassen.<\/jats:p><jats:p>\n            Menopausale Beschwerden dauern sehr viel l\u00e4nger als fr\u00fcher gedacht. Frauen mit ersten Hitzewallungen in der Pr\u00e4menopause oder fr\u00fchen Perimenopause erlebten in der SWAN-Studie (The Study of Women\u2019s Health Across the Nation) eine l\u00e4ngere Gesamtdauer der Beschwerden (Median &gt; 11,8 Jahre). Bei Frauen mit den ersten Hitzewallungen in der Postmenopause hielten die vasomotorischen Symptome (VMS) hingegen k\u00fcrzer an (Median: 3,4 Jahre).<\/jats:p><jats:p>\n            Bluthochdruck und Menopause Estrogen-Mangel als pr\u00e4disponierender Faktor f\u00fcr postmenopausalen Bluthochdruck ist relativ gut belegt, m\u00f6glicherweise haben Altern, Stress, und andere Faktoren jedoch noch eine h\u00f6here Relevanz. Der sch\u00fctzende Effekt einer menopausalen Hormontherapie ist nicht unumstritten.<\/jats:p><jats:p>\n            Behandlungsoptionen f\u00fcr menopausale VMS F\u00fcr die Behandlung der VMS empfehlen deutsche und internationale Leitlinien sowohl medikament\u00f6se als auch nicht medikament\u00f6se beziehungsweise nicht verschreibungspflichtige Optionen.<\/jats:p><jats:p>\n            Fezolinetant und Elinzanetant: neue Substanzen zur Behandlung von VMS In Deutschland wurde 2024 der erste Neurokinin-3-Rezeptor-Antagonist (Fezolinetant) als Vertreter einer neuen Substanzklasse zur VMS-Therapie bei postmenopausalen Frauen zugelassen. NK3R-Antagonisten k\u00f6nnen die KNDy-assoziierten Signalwege zur Aktivierung des Thermoregulationszentrums blockieren und so VMS reduzieren.<\/jats:p>","DOI":"10.1055\/a-2165-5935","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T22:53:29Z","timestamp":1729637609000},"page":"1317-1323","source":"Crossref","is-referenced-by-count":0,"title":["Was gibt es Neues zu Peri- und Postmenopause?"],"prefix":"10.1055","volume":"149","author":[{"given":"Katharina","family":"Tropschuh","sequence":"additional","affiliation":[{"name":"Frauenklinik, Universit\u00e4tsklinikum rechts der Isar, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanadin","family":"Seifert-Klauss","sequence":"additional","affiliation":[{"name":"Frauenklinik, Universit\u00e4tsklinikum rechts der Isar, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/GME.0000000000002090","article-title":"Effects of bothersome symptoms during the late reproductive stage and menopausal transition: observations from the Women Living Better Survey","volume":"30","author":"NF Woods","year":"2023","journal-title":"Menopause"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/13697137.2023.2225323","article-title":"What is in a name? A decade after changing from VVA to GSM have we come any closer to ending the \u2018silent suffering\u2019 of postmenopausal women with genitourinary symptoms?","volume":"26","author":"RE Nappi","year":"2023","journal-title":"Climacteric"},{"issue":"06","key":"ref4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/endrev\/bnab011","article-title":"\u201cHormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment\u201d","volume":"42","author":"VA Flores","year":"2021","journal-title":"Endocr Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"107950","DOI":"10.1016\/j.maturitas.2024.107950","article-title":"Vulvovaginal atrophy in women with and without a history of breast cancer: Baseline data from the PatiEnt satisfactiON studY (PEONY) in Italy","volume":"183","author":"MC Meriggiola","year":"2024","journal-title":"Maturitas"},{"issue":"09","key":"ref6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/GME.0000000000001805","article-title":"Symptom experience during the late reproductive stage and the menopausal transition: observations from the Women Living Better survey","volume":"28","author":"N Coslov","year":"2021","journal-title":"Menopause"},{"issue":"05","key":"ref7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/GME.0000000000002339","article-title":"\u201cNot feeling like myself\u201d in perimenopause \u2013 what does it mean? Observations from the Women Living Better survey","volume":"31","author":"N Coslov","year":"2024","journal-title":"Menopause"},{"issue":"08","key":"ref8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2019.6250.","article-title":"Diagnosing the Onset of Menopause","volume":"322","author":"N Santoro","year":"2019","journal-title":"JAMA"},{"key":"ref9","first-page":"590","article-title":"Hitzewallungen \u2013 haben wir neue Alterantiven zu Hormonersatztherapie?","volume":"67","author":"V Seifert-Klauss","year":"2024","journal-title":"Internistische praxis"},{"key":"ref10","first-page":"764","article-title":"Hormontherapie bei Frauen \u00fcber 60 Jahren?","volume":"11","author":"J Stepan","year":"2023","journal-title":"Frauenarzt"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Study of Women\u2019s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"NE Avis","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11897-024-00672-y","article-title":"The Pathophysiology, Prognosis and Treatment of Hypertension in Females from Pregnancy to Post-menopause: A Review","volume":"21","author":"S Li","year":"2024","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"ref13","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.14814\/phy2.15298","article-title":"Heart rate variability as a function of menopausal status, menstrual cycle phase, and estradiol level","volume":"10","author":"S Ramesh","year":"2022","journal-title":"Physiol Rep"},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"WB White","year":"2005","journal-title":"Circulation"},{"issue":"06","key":"ref15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4103\/ijmr.IJMR_478_20","article-title":"Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women","volume":"154","author":"A \u0110ogo","year":"2021","journal-title":"Indian J Med Res"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/endrev\/bnab011","article-title":"\u201cHormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment\u201d","volume":"42","author":"VA Flores","year":"2021","journal-title":"Endocr Rev"},{"issue":"07","key":"ref17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"\u201cThe 2022 hormone therapy position statement of The North American Menopause Society\u201d","volume":"29","author":"The Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel","year":"2022","journal-title":"Menopause"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"dgad058","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT (Skylight 2)","author":"KA Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/GME.0000000000002138","article-title":"Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)","volume":"30","author":"JA Simon","year":"2023","journal-title":"Menopause"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2414618","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials","author":"JV Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"04","key":"ref21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ogc.2018.07.004","article-title":"Menstrual Cycle Hormone Changes Associated with Reproductive Aging and How They May Relate to Symptoms","volume":"45","author":"A Allshouse","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"volume-title":"Hyperthyreose","year":"2020","author":"M Schott","key":"ref22"},{"volume-title":"Hyperparathyreoidismus","year":"2020","author":"H Siggelkow","key":"ref23"},{"issue":"06","key":"ref24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11940-008-0049-2.","article-title":"Use of oral contraceptives and postmenopausal hormone replacement: evidence on risk of stroke","volume":"10","author":"PH Davis","year":"2008","journal-title":"Curr Treat Options Neurol"},{"issue":"04","key":"ref25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1210\/jc.2011-3362.","article-title":"Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"SD Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"06","key":"ref26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1055\/a-1361-1948","article-title":"\u201cPerimenopause and Postmenopause \u2013 Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015\u2013062, September 2020)\u201d","volume":"81","author":"EC Inwald","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/GME.0000000000002350","article-title":"Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause","volume":"31","author":"JV Pinkerton","year":"2024","journal-title":"Menopause"},{"issue":"10","key":"ref28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"\u201cMenopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women\u2019s Health Initiative Randomized Trials\u201d","volume":"318","author":"JE Manson","year":"2017","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/01.AOG.0000158120.47542.18.","article-title":"Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women\u2019s Health Initiative","volume":"105","author":"VM Barnabei","year":"2005","journal-title":"Obstet Gynecol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"845180","DOI":"10.4061\/2010\/845180","article-title":"Progesterone and bone: actions promoting bone health in women","author":"V Seifert-Klauss","year":"2010","journal-title":"J Osteoporos"},{"issue":"08","key":"ref31","first-page":"S624","article-title":"Gyn\u00e4kologische Malignome und Hormontherapie: Beeinflusst eine Hormontherapie die Prognose von gyn\u00e4kologischen Malignomen?","volume":"59","author":"V Seifert-Klauss","year":"2018","journal-title":"Frauenarzt"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2165-5935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:00:39Z","timestamp":1730815239000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2165-5935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":30,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2165-5935","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}